Safety is predictable with NERLYNX3
MOST COMMON ADVERSE REACTIONS (≥5%) IN THE ExteNET TRIAL3
There was no evidence of cardiac or serious pulmonary toxicity nor increased risk for secondary malignancy observed in ExteNET2,21
*Includes abdominal pain, abdominal pain upper, and abdominal pain lower.
†Includes rash, rash erythematous, rash follicular, rash generalized, rash pruritic, rash pustular, rash maculo-papular, rash papular, dermatitis, dermatitis acneiform, and toxic skin eruption.
‡Includes stomatitis, aphthous stomatitis, mouth ulceration, oral mucosal blistering, mucosal inflammation, oropharyngeal pain, oral pain, glossodynia, glossitis, and cheilitis.
§Includes nail disorder, paronychia, onychoclasis, nail discoloration, nail toxicity, nail growth abnormal, and nail dystrophy.